Carl L Gordon

Carl L Gordon has an estimated net worth of $458 Million. This is based on reported shares across multiple companies, which include Adicet Bio, Inc., ArriVent Biopharma, Inc., COMPLETE GENOMICS INC, Turning Point Therapeutics, Inc., AMARIN CORP PLC\UK, Keros Therapeutics, Inc., Intellia Therapeutics, Inc., Theseus Pharmaceuticals, Inc., Alector, Inc., Kinnate Biopharma Inc., SpringWorks Therapeutics, Inc., ACADIA PHARMACEUTICALS INC, Pacira Pharmaceuticals, Inc., BIOCRYST PHARMACEUTICALS INC, ARMO BioSciences, Inc., Prevail Therapeutics Inc., Gemini Therapeutics, Inc. /DE, BiomX Inc., SELECTA BIOSCIENCES INC, Terns Pharmaceuticals, Inc., Oric Pharmaceuticals, Inc., Compass Therapeutics, Inc., Arsanis, Inc., ACCELERON PHARMA INC, MBX Biosciences, Inc., and Lomond Therapeutics Holdings, Inc..

2023 was Carl L Gordon's most active year for acquiring shares with 36 total transactions. Carl L Gordon's most active month to acquire stocks was the month of January. 2011 was Carl L Gordon's most active year for disposing of shares, totalling 48 transactions. Carl L Gordon's most active month to dispose stocks was the month of February. 2019 saw Carl L Gordon paying a total of $29,302,284.00 for 26,549,042 shares, this is the most they've acquired in one year. In 2018 Carl L Gordon cashed out on 8,255,806 shares for a total of $206,125,690.00, their largest year based on trade value.